Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.38 |
| ▸ | HRH2 | P25021 | 9/20 | 0.38 |
| ▸ | HRH1 | P35367 | 9/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094059 | 0.86 | HRH2 (0.42) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL7244499 | 0.84 | HRH2 (0.38) | HRH3HRH2HRH1HTR7MEN1 | |
| SCHEMBL7242820 | 0.83 | HRH3 (0.40) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL7249360 | 0.83 | HRH3 (0.46) | HRH3HRH2HRH1 | |
| SCHEMBL7248462 | 0.82 | HRH3 (0.39) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL7033710 | 0.81 | HRH2 (0.38) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL5965605 | 0.80 | HRH2 (0.38) | HRH3HRH2HRH1HTR7KCNH2 | |
| SCHEMBL2958755 | 0.80 | KCNH2 (0.42) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL7243888 | 0.78 | HTR7 (0.40) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL7248526 | 0.78 | NSD2 (0.40) | HRH3HRH2HRH1HTR7CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| EP-1244631-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001047893-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | HRH3 742/4885HRH2 321/4885HRH1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.